Category: Economics

Categories
Culture Economics Education Government Lifestyle Local News Programs & Events

Applications now open for Mercer County Student Internship Program

MERCER COUNTY — Applications are now open for the 2024 Mercer County Student Internship Program.

High school and college students who live, or attend school, in Mercer County may apply to a wide range of full-time and part-time internship positions. Internship opportunities are available over the summer from June through Labor Day, with a limited number of spots also available over the Winter Break and Spring Break periods.

“I’m excited for the Mercer County Student Internship Program to return this year,” said County Executive Dan Benson. “These positions offer us an opportunity to engage our next generation of leaders in the important work of county government. We all benefit from the energy and enthusiasm that they bring to the work.”

Students in the program will have the opportunity to serve the public by assisting the core day-to-day work of a department or division within the Mercer County government, while acquiring valuable experience for their future careers. Participants will also benefit from a series of activities planned by the Office of Personnel, curated to teach valuable skills, enhance workforce preparedness, and provide information about career paths in public service.

Interested students can visit the Mercer County website to apply, find information on the program, and read details on available positions.

College students will be paid $17/hour and high school students will earn $15.14/hour. All applicants must be at least 15 years of age. Students seeking to earn credits for their college or university have the option of working without pay.

The application deadline for Summer Student Internships is May 3

For additional information, please reach out to Theo Siggelakis at TSiggelakis@Mercercounty.org

Categories
Business Economics Healthcare Lifestyle Local News Perspectives Science

CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 results

  • 2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%*
    • Adjusted operational growth excluding COVID-19 Vaccine of 7.7%*
  • 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%*

  • Company increasing the midpoint for Full-Year 2024 operational sales5 and adjusted operational EPS guidance

 

 

NEW BRUNSWICK, N.J. — (BUSINESS WIRE) — In the section titled “Full-Year 2024 Guidance,” in the table, row titled “Operational Sales2,5/ Mid-point,” the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B).

 

The updated release reads:

JOHNSON & JOHNSON REPORTS Q1 2024 RESULTS

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer. “Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse.”

 

Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson & Johnson.

 

Overall Financial Results

Q1

($ in Millions, except EPS)

2024

2023

% Change

Reported Sales

$21,383

$20,894

2.3%

Net Earnings/(Loss)

$5,354

($491)

EPS (Diluted/Basic)6

$2.20

($0.19)

Q1

Non-GAAP* ($ in Millions, except EPS)

2024

2023

% Change

Operational Sales1,2

3.9%

Adjusted Operational Sales1,3

4.0%

Adjusted Operational Sales ex. COVID-19 Vaccine1,3

7.7%

Adjusted Net Earnings1,4

$6,580

$6,340

3.8%

Adjusted EPS (Diluted)1,4

$2.71

$2.41

12.4%

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

4

Excludes intangible amortization expense and special items

5

Excludes COVID-19 Vaccine

6

Basic shares are used to calculate loss per share in the first quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive

Note: Values may have been rounded

Regional Sales Results

Q1

% Change

($ in Millions)

2024

2023

Reported

Operational1,2

Currency

Adjusted

Operational1,3

U.S.

$11,620

$10,782

7.8%

7.8

–

7.9

International

9,763

10,112

(3.4)

(0.3)

(3.1)

(0.3)

Worldwide

$21,383

$20,894

2.3%

3.9

(1.6)

4.0

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: Values may have been rounded

Segment Sales Results

Q1

% Change

($ in Millions)

2024

2023

Reported

Operational1,2

Currency

Adjusted

Operational1,3

Innovative Medicine

$13,562

$13,413

1.1%

2.5

(1.4)

2.5

MedTech

7,821

7,481

4.5

6.3

(1.8)

6.5

Worldwide

$21,383

$20,894

2.3%

3.9

(1.6)

4.0

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Values may have been rounded

 

First Quarter 2024 Segment Commentary:

Operational sales* reflected below excludes the impact of translational currency. Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.

 

Innovative Medicine

Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 8.3%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), CARVYKTI (ciltacabtagene autoleucel), TECVAYLI (teclistamab-cqyv) and Other Oncology in Oncology, UPTRAVI (selexipag) and OPSUMIT (macitentan) in Pulmonary Hypertension, TREMFYA (guselkumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Including the COVID-19 Vaccine, Innovative Medicine worldwide operational sales grew 2.5%*.

 

MedTech

MedTech worldwide operational sales grew 6.3%* driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery.

 

Notable New Announcements in the Quarter:

The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, www.factsabouttalc.com, and www.LLTManagementInformation.com.

 

Regulatory

CARVYKTI is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received At Least One Prior Line of Therapy1

Press Release

Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults

Press Release

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

Press Release

U.S. FDA Approves OPSYNVI (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Press Release

U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma

Press Release

Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis

Press Release

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

Press Release

RYBREVANT (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Press Release

Janssen Receives Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma

Press Release

TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

Press Release

Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)

Press Release

Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

Press Release

Data Release

Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting1

Press Release

Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.241

Press Release

RYBREVANT (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer

Press Release

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

Press Release

Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine

Press Release

Johnson & Johnson reports positive topline results for Nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD)

Press Release

Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU

Press Release

Product Launch

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform

Press Release

Other

Johnson & Johnson to Acquire Shockwave Medical1

Press Release

Johnson & Johnson Completes Acquisition of Ambrx

Press Release

1 Subsequent to the quarter

 

Full-Year 2024 Guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

($ in Billions, except EPS)

April 2024

January 2024

Adjusted Operational Sales1,2,5

Change vs. Prior Year / Mid-point

5.5% – 6.0% / 5.8%

5.0% – 6.0% / 5.5%

Operational Sales2,5/ Mid-point

Change vs. Prior Year / Mid-point

$88.7B – $89.1B / $88.9B

5.5% – 6.0% / 5.8%

$88.2B – $89.0B / $88.6B

5.0% – 6.0% / 5.5%

Estimated Reported Sales3,5/ Mid-point

Change vs. Prior Year / Mid-point

$88.0B – $88.4B / $88.2B

4.7% – 5.2% / 5.0%

$87.8B – $88.6B / $88.2B

4.5% – 5.5% / 5.0%

Adjusted Operational EPS (Diluted)2,4/ Mid-point

Change vs. Prior Year / Mid-point

$10.60 – $10.75 / $10.68

6.9% – 8.4% / 7.7%

$10.55 – $10.75 / $10.65

6.4% – 8.4% / 7.4%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.57 – $10.72 / $10.65

6.6% – 8.1% / 7.4%

$10.55 – $10.75 / $10.65

6.4% – 8.4% / 7.4%

1

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2

Non-GAAP financial measure; excludes the impact of translational currency

3

Calculated using Euro Average Rate: April 2024 = $1.08 and January 2024 = $1.09 (Illustrative purposes only)

4

Non-GAAP financial measure; excludes intangible amortization expense and special items

5

 Excludes COVID-19 Vaccine

Note: Percentages may have been rounded

 

Other modeling considerations will be provided on the webcast.

 

Webcast Information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company’s website at events-and-presentations.

 

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

 

Non-GAAP Financial Measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at quarterly results.

 

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company’s website at quarterly results.

 

Note to Investors Concerning Forward-Looking Statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc; and Kenvue’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

 

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)

FIRST QUARTER

Percent Change

2024

2023

Total

Operations

Currency
Sales to customers by
segment of business
Innovative Medicine (1)
U.S.

7,612

7,023

8.4

8.4

–

International

5,950

6,390

(6.9

)

(4.0

)

(2.9

)

13,562

13,413

1.1

2.5

(1.4

)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S.

7,612

7,023

8.4

8.4

–

International

5,925

5,643

5.0

8.3

(3.3

)

13,537

12,666

6.9

8.3

(1.4

)
MedTech
U.S.

4,008

3,759

6.6

6.6

–

International

3,813

3,722

2.4

6.1

(3.7

)

7,821

7,481

4.5

6.3

(1.8

)
U.S.

11,620

10,782

7.8

7.8

–

International

9,763

10,112

(3.4

)

(0.3

)

(3.1

)
Worldwide

21,383

20,894

2.3

3.9

(1.6

)
U.S.

11,620

10,782

7.8

7.8

–

International

9,738

9,365

4.0

7.4

(3.4

)
Worldwide excluding COVID-19 Vaccine (1)

$

21,358

20,147

6.0

%

7.6

(1.6

)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) FIRST QUARTER

Percent Change

2024

2023

Total

Operations

Currency
Sales to customers by
geographic area
U.S.

$

11,620

10,782

7.8

%

7.8

–

Europe

5,163

5,590

(7.6

)

(7.7

)

0.1

Western Hemisphere excluding U.S.

1,194

1,076

11.0

21.3

(10.3

)
Asia-Pacific, Africa

3,406

3,446

(1.1

)

5.0

(6.1

)
International

9,763

10,112

(3.4

)

(0.3

)

(3.1

)
Worldwide

$

21,383

20,894

2.3

%

3.9

(1.6

)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) FIRST QUARTER

Percent Change

2024

2023

Total

Operations

Currency
Sales to customers by
geographic area (ex. COVID-19 Vaccine)
U.S.*

$

11,620

10,782

7.8

%

7.8

–

Europe(1)

5,138

4,843

6.1

6.0

0.1

Western Hemisphere excluding U.S.*

1,194

1,076

11.0

21.3

(10.3

)
Asia-Pacific, Africa*

3,406

3,446

(1.1

)

5.0

(6.1

)
International

9,738

9,365

4.0

7.4

(3.4

)
Worldwide

$

21,358

20,147

6.0

%

7.6

(1.6

)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
*No COVID-19 Vaccine sales
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) FIRST QUARTER

2024

2023

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)
Sales to customers

$

21,383

100.0

$

20,894

100.0

2.3

Cost of products sold

6,511

30.4

6,687

32.0

(2.6

)
Gross Profit

14,872

69.6

14,207

68.0

4.7

Selling, marketing and administrative expenses

5,257

24.6

4,906

23.5

7.2

Research and development expense

3,542

16.6

3,455

16.6

2.5

In-process research and development impairments

–

–

49

0.2

Interest (income) expense, net

(209

)

(1.0

)

14

0.1

Other (income) expense, net

(322

)

(1.5

)

6,940

33.2

Restructuring

164

0.8

130

0.6

Earnings/(loss) before provision for taxes on income

6,440

30.1

(1,287

)

(6.2

)
Provision for/(Benefit from) taxes on income

1,086

5.1

(796

)

(3.9

)
Net earnings/(loss) from Continuing Operations

$

5,354

25.0

$

(491

)

(2.3

)
Net earnings from Discontinued Operations, net of tax

–

423

Net earnings/(loss)

$

5,354

$

(68

)
Net earnings (loss) per share (Diluted/Basic) from Continuing Operations

$

2.20

$

(0.19

)
Net earnings per share (Diluted) from Discontinued Operations

$

–

$

0.16

Average shares outstanding (Diluted/Basic)

2,430.1

2,605.5

*
Effective tax rate from Continuing Operations

16.9

%

61.8

%
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations

$

7,877

36.8

$

7,536

36.1

4.5

Net earnings from Continuing Operations

$

6,580

30.8

$

6,340

30.3

3.8

Net earnings per share (Diluted) from Continuing Operations

$

2.71

$

2.41

12.4

Average shares outstanding (Diluted)

2,430.1

2,634.3

Effective tax rate from Continuing Operations

16.5

%

15.9

%
*Basic shares are used to calculate loss per share in the first quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

First Quarter
(Dollars in Millions Except Per Share Data)

2024

2023
Net Earnings/(loss) from Continuing Operations, after tax- as reported

$5,354

($491

)
Pre-tax Adjustments
Litigation related

–

6,900

Intangible Asset Amortization expense

1,078

1,122

COVID-19 Vaccine related costs 1

9

444

Restructuring related 2

171

130

Medical Device Regulation 3

51

64

Acquisition, integration and divestiture related

148

42

(Gains)/losses on securities

(20

)

72

IPR&D impairments

–

49

Tax Adjustments
Tax impact on special item adjustments 4

(229

)

(1,980

)
Tax legislation and other tax related

18

(12

)
Adjusted Net Earnings from Continuing Operations, after tax

$6,580

$6,340

Average shares outstanding (Diluted)

2,430.1

2,634.3

Adjusted net earnings per share from Continuing Operations (Diluted)

$2.71

$2.41

Operational adjusted net earnings per share from Continuing Operations (Diluted)

$2.72

Notes:

1

 COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company’s completion of its COVID-19 vaccine contractual commitments.

2

 In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $144 million in the fiscal first quarter of 2024 and $130 million in the fiscal first quarter of 2023 include the termination of partnered and non-partnered program costs and asset impairments.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $27 million in the fiscal first quarter of 2024 primarily includes costs related to market and product exits.

3

 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments’ measures of profit and loss used for making operating decisions and assessing performance which will be completed during 2024.

4

 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Contacts

Media contact:
Tesia Williams

media-relations@its.jnj.com

Investor contact:

Jessica Moore

investor-relations@its.jnj.com

Read full story here

Categories
Business Culture Economics Lifestyle News Now!

TD Bank announces Matt Boss as head of US Consumer Banking

CHERRY HILL, N.J. — (BUSINESS WIRE) — $TD #banking—TD Bank, America’s Most Convenient Bank®, recently elevated Matthew (Matt) Boss to Head of U.S. Consumer Banking. In his expanded role, Boss is responsible for TD’s more than 1,100 store locations, contact centers, digital sales and capabilities, retail operations, U.S. Wealth, and TD Auto Finance, while continuing to oversee all consumer product teams, including deposit products, credit cards and unsecured lending and residential lending.

 

“Matt is a strong, forward-thinking leader with a keen focus on delivering results through a culture based on performance and accountability,” said Leo Salom, President and CEO, TD Bank, AMCB. “His customer-centric approach, ability to drive best-in-class products and services from development to delivery, and deep commitment to fortifying our governance risk and controls will serve him well in his new role and position TD Bank for continued success here in the U.S.”

 

With nearly 25 years of banking experience, Boss joined TD Bank in 2017 to lead its Credit Cards and Unsecured Lending portfolios before being promoted to Head of Consumer Product Management in the U.S. Under his leadership, the bank scaled its deposit business while overhauling its overdraft policy, transformed the cards franchise, and optimized its mortgage operations. Boss has also made significant progress in attracting and retaining top talent across his teams and currently oversees the bank’s diversity and inclusion strategy as Chair of the Diversity Leadership Team.

 

“I’m excited about the path ahead for TD and the U.S. Consumer Bank,” said Boss. “We’ve built a strong franchise over the past few decades and have recently introduced a number of product innovations and capability enhancements, but we have so much more to do. It’s as important as ever that we continue to evolve our strategic approach to the business to ensure we’re well-positioned to provide even more value to our customers and communities in the years to come.”

 

Prior to TD, Boss served as the Managing Director of Products and Marketing for Melbourne-based Australia & New Zealand Banking Group (ANZ). In that role, he led the product functions for the retail and commercial bank, including responsibility for digital channels and assets, end-to-end marketing, data and analytics. Boss also spent more than a decade at Bank of America leading teams in the U.S. and England in roles of increasing responsibility across product, marketing, credit cards, and strategy.

 

Outside of TD, Boss serves as a board member of the National Forest Foundation and the Consumer Bankers Association. He earned a Bachelor’s degree in business administration and finance from the University of Massachusetts – Amherst.

 

About TD Bank, America’s Most Convenient Bank®

TD Bank, America’s Most Convenient Bank, is one of the 10 largest banks in the U.S. by assets, providing over 10 million customers with a full range of retail, small business and commercial banking products and services at more than 1,100 convenient locations throughout the Northeast, Mid-Atlantic, Metro D.C., the Carolinas and Florida. In addition, TD Auto Finance, a division of TD Bank, N.A., offers vehicle financing and dealer commercial services. TD Bank and its subsidiaries also offer customized private banking and wealth management services through TD Wealth®. TD Bank is headquartered in Cherry Hill, N.J. To learn more, visit www.td.com/us. Find TD Bank on Facebook at www.facebook.com/TDBank and on Instagram at www.instagram.com/TDBank_US/.

 

TD Bank is a subsidiary of The Toronto-Dominion Bank, a top 10 North American bank. The Toronto-Dominion Bank trades on the New York and Toronto stock exchanges under the ticker symbol “TD”. To learn more, visit www.td.com/us.

Contacts

Miranda Garrison

Miranda.Garrison@td.com

Categories
Business Culture Economics Lifestyle Local News Programs & Events Sports & Gaming

The AACCNJ announces Malcolm Jenkins as Juneteenth Black Business 2024 Expo speaker

Retired NFL Veteran, Entrepreneur, and Philanthropist Malcolm Jenkins will join John Harmon in a conversation about his career and professional journey as an entrepreneur.

 

 

TRENTON, N.J. – The African American Chamber of Commerce of New Jersey (AACCNJ) announced Malcolm Jenkins as the Keynote Speaker, for the Juneteenth Black Business 2024 Expo, which will be held at Fairleigh Dickinson University – Metropolitan Campus Teaneck, N.J., on June 13, 2024, from 9 a.m. to  4 p.m.

New Jersey native Malcolm Jenkin is a 13-year NFL veteran, two-time Super Bowl champion, three-time Pro-Bowl honoree, NFLPA Executive Committee Board Member, entrepreneur, philanthropist, executive director, published author, an Ohio State Athletics Hall of Fame Inductee, CNN Contributor, and advocate for social justice.

Jenkins created MALCOLM INC., a holding company for the various business verticals he co-founded; LISTEN UP MEDIA, a multimedia production company with the mission to showcase and distribute content that creates social awareness around systemic issues in society; BROAD STREET VENTURES, a $10 million investment vehicle funded entirely by Black and Brown investors including a group of fellow NFL players; DISRUPT FOODS, a multi-unit franchise developer and operator of 20+ quick service restaurants aiming to level the economic playing field for Blacks and Hispanics through Franchise Ownership; and DAMARI, a custom clothing company which includes ready-to-wear and made-to-measure men and women suits. As a philanthropist Jenkins strives to make a positive difference in the lives of youth in underserved communities through his non-profit, public charity, THE MALCOLM JENKINS FOUNDATION, who are proud members of the AACCNJ.

“I am humbled to stand alongside the African American Chamber of Commerce of New Jersey for their Second Annual Black Business Expo. As we honor Juneteenth and delve into “The Journey Continues,” I am eager to share my journey in entrepreneurship and what it’s taught me about the enduring spirit of our community. In spaces like these, we chart a course forward, fueled by innovation, collaboration, and unwavering determination,” said Malcolm Jenkins.

“We are extremely excited to have Malcolm Jenkins share his full portfolio of experience and commitment to demonstrating Black Excellence every day, said John E. Harmon, Sr., IOM, Founder, President & CEO, AACCNJ. “His voice is critical today and beyond as we drive our mission of an equitable coexistence in New Jersey and America,” said Harmon.

Categories
Business Culture Economics Lifestyle Local News Programs & Events

Mercer County announces second phase of zero-interest rate loans to businesses through a partnership with the UCEDC

MERCER COUNTY — Mercer County Exec. Dan Benson and the Board of County Commissioners are excited to announce that the County will partner for a second phase with UCEDC to establish a 0% Interest Loan Program for small businesses in Mercer County.

Dedicating an additional $240,000 in American Rescue Plan Act (ARPA) dollars, to be administered through the Mercer County Office of Economic Development, the program will allow Mercer County businesses to apply for affordable access to capital. The UCEDC will provide loans on a first-come, first-served basis utilizing current lending products and capital.

“Small businesses represent the life-blood of our local economy here in Mercer County, “said Mercer County Exec. Benson.

“In extending our interest-free loan program we are excited to give our Mercer County small businesses a meaningful jolt to spur economic development.”

“We are thrilled that Mercer County is extending UCEDC’s contract, leveraging another $500K in interest-free loans. This will provide more assistance to entrepreneurs, building on the $750K we’ve already distributed through our partnership. It’s a privilege to contribute to the success of Mercer County small businesses and make a positive impact on local communities in New Jersey,” said UCEDC President Adam Farrah.

The program will require the following:

  • Businesses must be located in Mercer County, registered with the State of New Jersey and must have been formed on or before September 1, 2019.
  • Businesses must have 30 full-time equivalent employees or less at time of application and have less than $10 million in annual gross revenue based on most recent tax return.
  • Loans will range from $10,000 to $20,000.
  • Loans will be offered at 0% interest, with a five-year repayment term.
  • Funds can be used for working capital, inventory, or purchases of furniture and equipment.
  • No collateral requirements, pre-payment penalties, processing, closing, or application fees will be required.
  • Personal guarantees of the significant owners of the business (10% or greater) are required.
  • Applicants must not have had a bankruptcy or significant charge-offs within the most recent 3-year period.

Based on the maximum loan amount of $20,000 and the parameters above, Mercer County will provide funding to approximately 26 businesses in the target market.

Please click here to see the flyer for the Mercer County Zero-Interest Loan Program or here to apply.

For additional information, please reach out to Theo Siggelakis at TSiggelakis@Mercercounty.org

Categories
Business Culture Economics Foodies/Tastylicious International & World Lifestyle Local News Science

Innophos upgrades production facility for EC grade calcium phosphates

CRANBURY, N.J. — (BUSINESS WIRE) — Innophos, a leader in the food and nutritional ingredient industry, is excited to announce a significant upgrade in its production facility for EC (European Commission) grade calcium phosphates. This capital investment is a strategic move to meet the growing demand in the EU food and dietary supplement markets.

 

This investment at Innophos’ Chicago Heights, IL production facility will result in greater manufacturing flexibility and is set to enhance the company’s ability to supply high-quality, EC grade calcium phosphates, long known for their purity, consistency, and compliance with stringent European regulatory standards.

 

Migue DeJong, Commercial Director, stated, “This investment reflects our commitment to providing our European customers with top-tier products and services. We recognize the growing need for high-quality calcium phosphates in the food, health, and wellness industry, and we are poised to meet this demand with our enhanced production capabilities.”

 

Calcium phosphates are essential ingredients in dietary supplements, food and beverage products, and infant food and formula contributing to bone health and overall well-being. Innophos’ EC grade calcium phosphates are specifically designed to blend seamlessly into various formulations, offering excellent bioavailability and stability.

 

For more information about Innophos’ EC grade calcium phosphates and other products, please visit our website.

 

About Innophos

Innophos is a leading global producer of specialty phosphate and mineral solutions serving food, beverage, nutrition, and industrial markets. Leveraging our expertise in phosphate science and technology, we partner with our customers to innovate and deliver products that excel in quality and performance. Headquartered in Cranbury, New Jersey, Innophos has an integrated manufacturing footprint that spans the United States, Canada, Mexico, and China. For more information, please visit www.innophos.com.

Contacts

Carrie Livingston

Email: carrie@colinkurtis.com
Phone: 815-519-8302

Categories
Business Culture Economics Government Lifestyle Local News Perspectives Politics Programs & Events

County Exec. Benson releases 100-day accomplishments since his office election

MERCER COUNTY — It has been 100 days since Mercer County Executive Dan Benson was sworn into office on Jan. 1,  2024.

“When we took office, the county faced considerable challenges. The 2022 county audit wasn’t complete, several key financial statements needed corrections, and a key county bond was near its expiration. In our first 100 days, we have put Mercer County on stable footing. We have an experienced team that has restored competence and professionalism to Mercer County government,” said County Executive Benson.

Benson immediately hired a qualified and experienced staff, led by Christopher Marion as County Administrator, Sharon Shinkle Gardner as Chief of Staff, Taraun Tice McKnight and Ana Montero as Deputy Administrators, and Nick Trasente as Chief Financial Officer. In the first 50 days, this team reorganized Mercer County government, making the following changes:

  • County Administrator Marion will oversee Buildings & Grounds, Corrections, Trenton-Mercer Airport, the Mercer County Library System, and the Joint Insurance Fund
  • Deputy Administrator Tice McKnight will oversee Human Services, Mercer County Office of Training and Employment Services (One-Stop Career Center), Housing, and Veterans Affairs
  • Deputy Administrator Montero will oversee a new joint department of Public Health and Safety, including the Office of Emergency Management and Emergency Communications

“While working to fix the county’s finances, we have also laid the foundation for the work ahead. We’ve improved accessibility, fostered greater collaboration with our municipalities, increased transparency to public contracting, modernized our County Code, and ensured our administration is both diverse and transparent,” said County Executive Benson.

Highlights of the Benson Administration’s first 100 days in office include:

  • Completed the long overdue 2022 Mercer County Audit
  • Shared updates on IRS penalties incurred from the last administration with the Board of Commissioners
  • Drafted initial revisions to the Mercer County Code, the first set of revisions in over ten years
  • Completed an April 4th bond note sale rolling over the $150+ million sale from the last administration, at a lower interest rate, while maintaining our bond rating
  • Worked with our new CFO and financial consultants to recreate and identify missing or incorrect County financial documents
  • Obtained a $70,000 grant to install hearing induction loops to assist the deaf and hard-of-hearing at select county facilities
  • Launched a new round of zero-interest loans for local small businesses
  • Provided funding to help Hamilton Township buy and preserve Kuser Woods
  • Completed a comprehensive After Action Review of Mercer County’s response to the COVID-19 pandemic
  • Appointed a diverse group of Mercer residents to numerous Boards and Commissions

Benson added, “There’s a lot of work still ahead, but we are committed to making sure Mercer County government works for everyone. We will do whatever it takes to make that pledge a reality.”

  • Hiring a new Office of Emergency Management Director
  • Establishing a Division of Tourism & Travel in Economic Development
  • Creating a Mercer County Office of LGBTQIA+ Services within Human Services
  • Breaking ground on the Trenton-Mercer Airport Firehouse (Aircraft Rescue and Fire Fighting facility)
  • Preparing the 2024 Mercer County Budget for adoption
  • Auditing Mercer County Information Technology Systems
  • Installing Wi-Fi at Trenton-Mercer Airport
  • Completing an audit of Mercer County Parks System.
  • Conducting a Corrections Facility Assessment
  • Hosting Bi-Annual Legislative Delegation meetings to discuss Mercer County’s priorities

“I am excited for the future of Mercer County and for our next 100 days and beyond,” said County Executive Benson. “Collaboration, transparency, and professionalism are cornerstones of our administration, and we are dedicated to keeping our community informed about our continued progress.”

For additional information, please reach out to Theo Siggelakis at TSiggelakis@Mercercounty.org.

Categories
Business Culture Digital - AI & Apps Economics Education Lifestyle Technology

AdvanSix to release first quarter financial results and hold Investor Conference Call on May 3

PARSIPPANY, N.J. — (BUSINESS WIRE) — AdvanSix (NYSE: ASIX) will issue its first quarter 2024 financial results before the opening of the New York Stock Exchange on Friday, May 3. The company will also hold a conference call with investors at 9 a.m. ET that day.

 

Presentation materials / Webcast details

A real-time audio webcast of the presentation can be accessed at http://investors.advansix.com. Related materials will be posted prior to the presentation at that site, and a replay of the webcast will be available on the AdvanSix investor website following the presentation.

 

Conference call details

To participate on the conference call, dial (844) 855-9494 (domestic) or (412) 858-4602 (international) approximately 10 minutes before the 9:00 a.m. ET start and tell the operator that you are dialing in for AdvanSix’s first quarter 2024 earnings call. A replay of the conference call will be available from 12 noon ET on May 3 until 12 noon ET on May 10. You can listen to the replay by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international). The access code is 7285784.

 

About AdvanSix

AdvanSix is a diversified chemistry company that produces essential materials for our customers in a wide variety of end markets and applications that touch people’s lives. Our integrated value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients, and chemical intermediates. More information on AdvanSix can be found at http://www.advansix.com.

 

Contacts

Media
Janeen Lawlor

(973) 526-1615

janeen.lawlor@advansix.com

Investors
Adam Kressel

(973) 526-1700

adam.kressel@advansix.com

Categories
Business Culture Digital - AI & Apps Economics Healthcare International & World Lifestyle Science

Talking Medicines reports record revenue bookings and strategic partnerships in Q1, 2024

GLASGOW, Scotland — (BUSINESS WIRE) — Talking Medicines, a pioneering leader in healthcare intelligence leveraging Advanced Data Science and Artificial Intelligence, is proud to announce a robust start to 2024, marked by record revenue bookings and significant advancements in its innovative platform Talking Medicines Drug-GPT. The Company is headquartered in Glasgow with a growing sales presence in New Jersey/New York/Philadelphia.

 

In the first quarter of 2024, Talking Medicines achieved significant success with its Talking Medicines Drug-GPT platform, revolutionizing access to intelligence on pharmaceutical medicine brands and disease areas. This innovative technology has garnered substantial interest from leading global healthcare advertising agencies, who recognize its potential to transform strategies for pharmaceutical clients.

 

Among Talking Medicines’ esteemed clientele are some of the world’s most prominent healthcare ad agency networks, reaffirming the platform’s efficacy in providing key insights derived from aggregated patient and healthcare professional conversations. By tapping into previously unseen data, Talking Medicines empowers its clients to drive better strategies and make informed decisions in relation to the pharmaceutical landscape.

 

Furthermore, Talking Medicines has forged strategic partnerships with both open and closed data communities, solidifying its commitment to expanding access to crucial insights. Notable among these partnerships is the collaboration with data aggregator Socialgist, which enables Talking Medicines to tap into millions of public conversational sites, enriching the Talking Medicines Drug-GPT platform with a wealth of diverse data sources.

 

Speaking on these achievements, Jo Halliday CEO expressed excitement about the company’s trajectory and the transformative impact of Talking Medicines Drug-GPT on the healthcare industry. “We are thrilled by the overwhelming response to Talking Medicines Drug-GPT and our strategic partnerships. This success underscores our dedication to empowering healthcare stakeholders with actionable insights derived from Advanced Data Science and Artificial Intelligence,” Jo Halliday, CEO stated.

 

Looking ahead, Talking Medicines remains committed to driving innovation and fostering collaborations that enhance healthcare decision-making through intelligence globally.

 

About Talking Medicines:

Talking Medicines based in Glasgow and New Jersey is a leading provider of healthcare intelligence, leveraging Advanced Data Science and Artificial Intelligence to transform pharmaceutical brand strategies. The company’s innovative platform, Talking Medicines Drug-GPT, revolutionizes access to intelligence on pharmaceutical medicine brands and disease areas, empowering healthcare stakeholders with actionable insights derived from aggregated patient and healthcare professional conversations. For more information, please visit www.talkingmedicines.com.

Contacts

Britt Gibson

Britteny@talkingmedicines.com
+1 551-280-9502

Categories
Business Culture Economics Entertainment News Lifestyle Perspectives

Box Office: ‘Godzilla x Kong’ to tower over ‘Monkey Man,’ ‘First Omen’

“Godzilla x Kong: The New Empire” is poised to stomp all over the box office competition… again.

 

After its better-than-expected debut, Warner Bros. and Legendary Entertainment’s monster tentpole has generated $95 million domestically and $210 worldwide to date. Now, “Godzilla x Kong” looks to add $32 million to $36 million in its second weekend of release.

 

Those ticket sales, down roughly 55% from its opening, will easily be enough to lead over two newcomers, director Dev Patel’s action-thriller “Monkey Man” and Disney and 20th Century’s supernatural prequel “The First Omen.”

 

“Monkey Man” is targeting $12 million to start, while “The First Omen” is projected to pull ahead with $14 million to $15 million. Holdovers, including “Kung Fu Panda 4,” “Dune: Part Two” and “Ghostbusters: Frozen Empire,” will otherwise round out box office charts.

 

“Monkey Man” was initially destined for Netflix and not the big screen. But Universal Pictures landed rights after Jordan Peele, whose production company has a distribution deal with the studio, saw and acquired the movie, feeling it was deserving of a theatrical release. It was picked up for $10 million, so it won’t take much to turn a profit in its big screen run.

 

Patel, in addition to directing in his feature debut, also stars in the politically charged film that takes on the Hindu caste system. He plays Kid, an anonymous man who exacts revenge on the corrupt leaders who are responsible for the death of his mother. Through his journey, he becomes the savior of the poor and powerless people. Reviews have been mostly positive, with Variety’s Owen Gleiberman praising the all the blood-soaked action. “The best thing about ‘Monkey Man’ is Patel’s staging of, and acting in, the fight scenes,” he wrote in his review. “They’re far more random and spontaneous than we’re used to, with a razory intensity.”

 

“The First Omen” is the sixth installment in the otherworldly franchise and its first new entry in 18 years. It’s eyeing a similar start to its series predecessor, 2006’s reboot “The Omen,” starring Liev Schriber and Julia Stiles. That film opened to $16 million and eventually powered to $119 million globally (not adjusted for inflation).

 

“The First Omen” was modestly budgeted and cost about $30 million to produce. This film, which takes place before the events of “The Omen,” follows an American woman (Nell Tiger Free) sent to work at a church in Rome. Once she’s there, she uncovers a sinister conspiracy to bring about the birth of the Antichrist.

 

Read More

 

 

— Variety